Gilenya (Fingolimod HCl) Patent Expiration, LOE Window & CMS Spending

Gilenya (Fingolimod HCl) by Novartis: FDA Orange Book LOE 2032-09-30, 15 AB generics, $89.6M 2024 CMS Part D & Medicaid spend, and 5 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN022527 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2032-09-30
Orange Book Patents (*PED Extensions)3 patents (1 *PED)
Active AB-Rated Generic Competitors15
2024 CMS Total Public Spend$89.6M
2024 Medicare Part D Spend$53.7M
2024 Medicaid Spend$36.0M
Reported Wholesale Price Change (CA SB 17)5 WAC filings (max 23.2% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.